Introduction
Neonatal respiratory distress syndrome (RDS) is still regarded, despite improved neonatal care facilities, as a major complication of premature births. Since the early clinical trials of Liggins & Howie (1972) , antenatal administration of glucocorticoids to the mother has been used in an attempt to reduce the incidence of RDS. In a recent review, Ballard & Ballard (1979) reported that the many clinical studies which have now been completed have established that both the incidence and severity of RDS can be decreased by the use of glucocorticoids.
Despite growing evidence of the usefulness of glucocorticoids in preventing RDS, very little is known of the disposition of these potent drugs in pregnant women. Several glucocorticoids have been used in this indication and for their use to be optimized, information must be gathered on the plasma levels of the various drugs, on their rates of elimination, and on their bioavailability after different routes of administration. Some work has been done by Tsuei et al. (1980) who examined the disposition and placental transfer of dexamethasone in pregnant women approaching delivery. Also, Ballard et al. (1975) measured betamethasone and cortisol levels in pregnant women after a 12 mg dose of betamethasone as a 'sustained release' formulation. In that study, cortisol levels were measured using a CBG-isotope assay and total glucocorticoid levels using a radioreceptor assay; the difference was attributed to betamethasone.
Betamethasone is the most commonly used glucocorticoid for the prevention of RDS in this hospital, and is administered either as Celestone Injection or as Celestone Chronodose. Celestone Injection consists of 5.3 mg/ml betamethasone disodium phosphate (BP), a soluble ester of betamethasone (BET), and may be administered intravenously (i.v.) or intramuscularly (i.m.); while Celestone Chronodose is a mixture of BP (4.0 mg/ml) in solution and betamethasone acetate (BA) (3.1 mg/ml) in suspension. The latter formulation is administered i.m.; the phosphate ester is expected to be rapidly released to the blood stream-while the acetate ester is included to provide a repository for 'sustained release'. Both esters are expected to be hydrolysed in vivo to the active glucocorticoid BET. To study fully the disposition of BET and endogenous cortisol after administration of these formulations, we have developed sensitive and specific analytical techniques for BP (Petersen et al., 1983b) , BET, BA and cortisol (Petersen et al., 1980a) in plasma.
We previously reported the placental transfer of BET (Petersen et al., 1980b) and its disposition after i.v. administration to non-pregnant (Petersen et al., 1983b) and pregnant (Petersen et al., 1983a) (Table 1 ). The dose was given into the upper, outer quadrant of a buttock using a 23G x 1 ½/2" needle, and the injection site was briefly massaged. Blood samples (8 ml) were drawn via a cannula in the forearm vein, using disposable plastic syringes, before dosing and at about 5, 15, 30, 45, 60, 90minand2, 3, 4, 5, 6, 7, 8, lOh after dosing. The blood was transferred to plastic tubes containing ammonium heparin and sodium arsenate (Petersen et al., 1980a) , then centrifuged and the plasma frozen at -22°C until analysed. Additional blood samples were drawn at delivery from the mother and from the (Petersen et al., 1980a (Petersen et al., , 1983b (Petersen et al., 1980a) . No detectable breakdown of either ester occurred when blood samples were treated in this way. Plasma samples from this patient group were analysed for BP, BA, BET and cortisol (Petersen et al., 1980a (Petersen et al., , 1983b .
Group III A group of patients (Nos 24-31) admitted to hospital the day before an elective caesarean section and for whom no glucocorticoids had been prescribed were included in this study to provide control plasma cortisol levels. Blood samples were collected on the day of admission, from the mother and umbilical cord vessels at delivery and from the mother between 08.00 h and 11.00 h on alternate mornings for up to 10 days post-partum. The plasma samples were analysed for cortisol (Petersen et al., 1980a) .
Pharmacokinetics and statistical analyses
Linear regression analysis was carried out on the terminal log-linear phase of the plasma concentration-time (C-t) curves to provide an estimate of the terminal-phase rate constant from which the plasma half-life (t½,) was calculated. Areas under the C-t curves (AUC) were calculated using the trapezoid rule with the appropriate extrapolation to infinite time (Gibaldi & Perrier, 1975) . When a patient was studied after a dose other than the first, the contribution from previous doses to AUC and peak plasma level was subtracted using the principle of superposition (Gibaldi & Perrier, 1975) . Differences between groups were tested using the Mann-Whitney U-Test (Goldstein, 1964) ; a two-sided test was applied and differences were considered significant when P < 0.05.
Results
After administration of the solution (Group I) into the gluteus maximus muscle, plasma concentrations of BP were measured in four patients. Peak concentrations were seen within 18-30 min, and ranged over 92-370 ng/ml (Figure la). After peaking the BP concentrations fell with a mean t/12 of 23.3 ± 7.6 min (± s.d.); AUC was highly variable ranging over 3.7-15.4 ,ug/ml min (mean 9.0 ± 5.5 ,ug/ml min). After dosing with BP, BET was not detected before 15 min and peak concentrations occurred at 60-130 min (Table 2) . Peak BET concentrations of 33-75 ng/ml were observed before the levels dropped exponentially with a mean t½, of 306 ± 93 min (Figure 2 ). The AUC for BET had a mean value of 29.0 ± 5.8 ,ug/ml min.
Patients who were studied after the first dose of the solution showed a steady drop in plasma cortisol concentrations over the 8-10 h sampling period (Figure 3 ). The mean half-life of decline was 267 ± 43 min and levels fell from predose concentrations between 150 ng/ml and 270 ng/ml to 20-30% of those levels after 8-10 h. Analysis of the samples drawn the morning after dosing showed the plasma concentrations of cortisol had dropped further to basal levels of 23-38 ng/ml (Table 3) . Patients studied after subsequent doses of BP showed little variation in their plasma cortisol levels over the 8-10 h sampling period (Figure 3 ).
After the i.m. administration of the suspension to patients (Group II), plasma samples were analysed for BP, BET and cortisol as before, and for BA. BP concentrations were measured in plasma samples from four patients who received the equivalent of 12 mg BET. Plasma BP concentrations did not simply peak and then decline as in the Group I subjects but were found to be erratic (Figure lb from the last two samples from each patient, but were similar to those observed in the Group I subjects. Mean AUC for BP was 5.7 ± 1.0 ,ug/ml min. BET was not observed in plasma before 15 min after dosing, and peak concentrations were seen between 45 min and 102 min (Table 4) . When the equivalent of 6 mg BET was given, peak concentrations were 23-25 ng/ ml (n = 3) and after the equivalent of 12 mg BET, a range of 35-63 ng/ml was observed. In all patients the plasma BET concentrations subsequently declined in a single exponential phase with a mean t½, of 317 + 74 min ( Figure  2 ). AUC for BET was normalised by dividing very similar to that observed in Group I patients. After the first dose of the suspension, cortisol levels fell smoothly over the next 8-10 h with a mean half-life of 258 ± 55 min (Figure 3 ) and the plasma sample collected the morning after dosing contained only 21-38 ng/ml (Table  3) (Figure 3 ).
Duration of adrenal suppression
In patients from Groups I and II whose labour was successfully stopped and premature delivery was avoided (subjects 4, 17, 19), plasma cortisol levels had begun to return to normal pregnancy levels with 2-3 days of the last dose of BET (Table 3) . When delivery occurred within 22-26 h of the last dose of BET, cortisol levels in the mother and the umbilical vessels were generally lower than in Group III patients (Table 5) but maternal levels were often higher than those measured some hours previously (Table 3) . A higher concentration of cortisol was always found in the umbilical artery than in the umbilical vein. After delivery, maternal cortisol levels in Group I and II patients increased Plasma cortisol levels in Group III patients (Nos 24-31) who were studied in the postpartum period tended to drop gradually from the elevated levels seen at delivery to approach their new non-pregnant levels (Table 3) . Cortisol levels in these patients 5-10 days postpartum were similar to those observed in Group I and II patients 5-10 days after the last dose of BET, when delivery had intervened.
Discussion
After i.m. administration oi the solution, the t½, of decline of BP plasma concentrations was five times greater than that observed after i.v. administration of the solution (Petersen et al., 1983a) , and probably reflected the rate of absorption of BP from the muscle rather than the very rapid elimination process. The mean AUC for BP after i.m. administration was 65% of that observed after the same dose was given i.v., indicating that a large proportion of BP reaches the bloodstream before hydrolysis to BET occurs (Figure 4) . Interindividual variability in the BP AUC was greater after i.m. administration and may have been due to variable extents of hydrolysis of BP to BET in the muscle. Importantly, wherever the hydrolysis of BP to BET occurred, the availability of BET to the systemic circulation was as high after i.m. injection as after i.v. administration, since the BET AUC after the two routes of administration were not significantly different (Petersen et al., 1983a) . The similarity in AUCs indicated that the relative bioavailability of BET both from the phosphate ester and from the i.m. injection site was excellent. However, peak concentrations of BET were lower (P < 0.05) and were reached later (P < 0.01) after an i.m. dose of BP than after the same dose of BP given i.v. (Petersen et al., 1983a) . In keeping with the comparable bioavailability and the lower, later peak concentrations observed after i.m. administration, BET concentrations in the terminal phase of the curve were higher than those observed after i.v. administration of the solution.
As may be expected, the administration of the solution by either route had a similar effect on plasma cortisol levels (Petersen et al., 1983a) . A slow decline in cortisol levels was observed over the 24 h following the first dose of BP. The minimum level reached (20-40 ng/ Muscle ml) was not further suppressed by subsequent doses of BP since this represented the basal production level that is generally thought not to be controlled by the negative feedback system (Ceresa et al., 1970) . After the completion of BET therapy, the return of normal cortisol production appeared to be rapid with increasing plasma levels observed in the mother 48 h after the last i.m. dose of the solution.
The absorption of BP from the muscle after administration of the suspension was more erratic than after i.m. solution, suggesting that the suspension formulation modifies this process. The AUC for BP after each of these formulations was similar when a correction for dose had been made, indicating that again a large proportion of BP reaches the systemic circulation before it is hydrolysed to BET. When the suspension was administered to patients, no BA was detected in any plasma sample, even those taken for up to 10 days after the last dose, so any release of BA from the muscle site to the bloodstream must have been extremely slow. Alternatively, BA may have slowly dissolved and been hydrolysed to BET in the muscle and released into the bloodstream as the active glucocorticoid (Figure 4 ). If this was the case, a prolongation of the terminal-phase t,,2 of BET might have been expected but was not observed; the half-life of BET in Group II patients was not different from that observed in Group I patients. Additionally, no BET was detected between the second and tenth days after the last dose of the suspension. The relative bioavailability of BET after i.m. (and i.v.) Maltau et al. (1979) and Ballard et al. (1975) found, as we did, that maternal cortisol levels fell to about 10-30% of predose levels in the 24 h after the first 12 mg dose of the suspension, and began to increase again 2-4 days after the last dose had been given. The number of doses used in these studies varied from one dose to three doses given 24 h apart. After this last regimen, Gennser et al. (1976) found that plasma cortisol levels in the umbilical cord remained low, at about 25 ng/ml, for 3-4 days after the last dose of the glucocorticoid. There was no difference between treated and control groups with respect to cord cortisol levels if delivery occurred 4 days or more after the last dose of BET. Ohrlander et al. (1977) , Sybulski (1977) and Ballard et al. (1980) have all found that neonates born with suppressed plasma cortisol levels have increasing adrenal function in their first neonatal day and are capable of responding normally to stress.
Our results indicated that the suspension provided no advantage over i.m. administration of the solution as regards duration of glucocorticoid activity. The relative bioavailability of BET from the former formulation was both low (65%) and variable making it considerably less reliable than the solution in terms of the plasma BET concentrations achieved. If sustained levels of glucocorticoid are required in the foetus for foetal lung maturation, the use of Celestone Injection in smaller doses and at shorter dosage intervals than are usually recommended for Celestone Chronodose would have the effect of decreasing plasma concentration fluctuations and maintaining sustained plasma concentrations of BET. Apart from the poor bioavailability of BET from the suspension, this formulation has the further disadvantage of being painful to the patient on injection, and it would appear from our data that at least part of the insoluble BA injected remains at the injection site for relatively long periods of time. In contrast, i.m. administration of the solution resulted in a bioavailability of BET similar to that seen after i.v. administration of the solution and so provided a formulation that was reliable and simpler to administer.
